Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births".

Journal of immunology research·2022
Same author

Longitudinal evaluation of diffusion tensor imaging and cognition in systemic lupus erythematosus.

Lupus·2018
Same author

Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births.

Journal of immunology research·2018
Same author

Functional Magnetic Resonance Imaging of Working Memory and Executive Dysfunction in Systemic Lupus Erythematosus and Antiphospholipid Antibody-Positive Patients.

Arthritis care & research·2016
Same author

Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.

The Netherlands journal of medicine·2014
Same author

Assisted reproductive technology in SLE and APS.

Lupus·2014

Related Experiment Video

Updated: Jul 5, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

New developments in lupus-associated antiphospholipid syndrome.

M D Lockshin1, R H W M Derksen

  • 1The Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Medical College of Cornel University, New York, New York, USA.

Lupus
|May 21, 2008
PubMed
Summary

Systemic lupus erythematosus is linked to antiphospholipid syndrome, the most common cause of secondary antiphospholipid syndrome. Pathogenesis and treatment show no clear distinction between primary and secondary antiphospholipid syndrome.

Related Experiment Videos

Last Updated: Jul 5, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Area of Science:

  • Rheumatology
  • Immunology
  • Vascular Medicine

Background:

  • Antiphospholipid syndrome (APS) was first described in patients with systemic lupus erythematosus (SLE) over 20 years ago.
  • SLE is the most frequent underlying condition in secondary APS.
  • The distinction between primary and secondary APS is often blurred.

Purpose of the Study:

  • To review the pathogenic concepts and treatment strategies for antiphospholipid syndrome.
  • To clarify the relationship between SLE and APS.
  • To determine if a clear distinction exists between primary and secondary APS.

Main Methods:

  • Literature review of pathogenic concepts in APS.
  • Analysis of treatment approaches for APS.
  • Comparison of primary and secondary APS based on current evidence.

Main Results:

  • Systemic lupus erythematosus is the primary associated condition for secondary APS.
  • No significant differences in pathogenesis or treatment were identified between primary and secondary APS.
  • The review highlights the overlap and shared characteristics of both forms of APS.

Conclusions:

  • A clear distinction between primary and secondary antiphospholipid syndrome is not consistently supported by current pathogenic concepts and treatment data.
  • Management strategies for APS should consider the underlying condition, often SLE, but core principles apply broadly.
  • Further research may be needed to refine classifications and targeted therapies for APS.